Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pan Tong

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Oncotarget|February 18, 2017
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerC Allison Stewart, Pan Tong, Robert J Cardnell, et al.
Cancer Research|August 16, 2017
HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell CarcinomasMianen Sun, Pan Tong, Wen Kong, et al.
Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.
Nature Communications|January 29, 2015
Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome AtlasRehan Akbani, Patrick Kwok Shing Ng, Henrica M J Werner, et al.
Nature Communications|May 30, 2014
A pan-cancer proteomic perspective on The Cancer Genome AtlasRehan Akbani, Patrick Kwok Shing Ng, Henrica M J Werner, et al.
Cancer Discovery|June 13, 2015
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesFerdinandos Skoulidis, Lauren A Byers, Lixia Diao, et al.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Cell Systems|October 1, 2018
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β SuperfamilyAnil Korkut, Sobia Zaidi, Rupa S Kanchi, et al.
Cancer Discovery|May 19, 2018
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Oncotarget|February 18, 2017
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancerC Allison Stewart, Pan Tong, Robert J Cardnell, et al.
Cancer Research|August 16, 2017
HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell CarcinomasMianen Sun, Pan Tong, Wen Kong, et al.
Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.
Nature Communications|January 29, 2015
Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome AtlasRehan Akbani, Patrick Kwok Shing Ng, Henrica M J Werner, et al.
Nature Communications|May 30, 2014
A pan-cancer proteomic perspective on The Cancer Genome AtlasRehan Akbani, Patrick Kwok Shing Ng, Henrica M J Werner, et al.
Cancer Discovery|June 13, 2015
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesFerdinandos Skoulidis, Lauren A Byers, Lixia Diao, et al.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Cell Systems|October 1, 2018
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β SuperfamilyAnil Korkut, Sobia Zaidi, Rupa S Kanchi, et al.
Cancer Discovery|May 19, 2018
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaFerdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, et al.
Pageof 6